Presentations
Upcoming Events
No upcoming events
Past Events
Unlocking efficacy and tolerability of LLD: Continuous immunostimulation enhances lenalidomide (LLD) response
Dr. Mohamad Hussein, Starton Scientific Committee Chair, in an exclusive interview with EBD Group…
Virtual CLL Investor Day
Starton Therapeutics is developing STAR-LLD for use in blood cancers including CLL. Topics:Starton continuous…